FrancophonIA/ELRC3.0 huggingface dataset:
English: Bullous dermatitis (toxic epidermal necrolysis, Stevens Johnson Syndrome, erythema multiforme), angioedema, drug induced hypersentsitivity syndrome, drug rash with eosinophilia and systemic symptoms (DRESS), rash erythematous or exfoliative, urticaria, eczema, lichen planus
Maltese: Dermatite bulloża (nekroliżi tossika talepidermis, is-Sindrome ta' Stevens Johnson, eritema multiforme), anġjoedima, sindromu ta' sensittività eċċessiva kkawżat millmediċina, raxx kkawżat mill-mediċina b'eosinofilja u sintomi sistemiċi (DRESS), raxx eritematożu jew bil-qoxra, urtikarja, ekżema u lichen planus
English: The CYP2C19*1 allele corresponds to fully functional metabolism while the CYP2C19*2 and CYP2C19*3 alleles correspond to nonfunctional metabolism.
Maltese: L-allel CYP2C19*1 jikkorrispondi ma' metaboliżmu kompletament funzjonali filwaqt li l-alleli CYP2C19*2 u CYP2C19*3 jikkorrispondu ma' metaboliżmu li mhuwiex funzjonali.
English: Following therapeutic doses, approximately 10% is found excreted in the urine as salicylic acid, 75% as salicyluric acid, 10% phenolic- and 5% acyl-glucuronides of salicylic acid.
Maltese: Wara dożi terapewtiċi, lekrezzjoni fl-awrini tkun ta' madwar 10% bħala salicylic acid, 75% bħala salicyluric acid, 10% fenoliku-u 5% aċilu-glukuronidi ta' salicylic acid.
English: The number of patients experiencing the primary endpoint [cardiovascular (CV) death, myocardial infarction (MI), or stroke] was 582 (9.3%) in the clopidogrel plus ASA group and 719 (11.4%) in the ASA group, a 20% relative risk reduction (RRR) (95% CI of 10%-28%; p=0.00009) for the clopidogrel plus ASA group [17% relative risk reduction when patients were treated conservatively, 29% when they underwent percutaneous transluminal coronary angioplasty (PTCA) with or without stent and 10% when they underwent coronary artery bypass graft (CABG)].
Maltese: In-numru ta' pazjenti li għaddew mill-punt primarju ta' tmien [mewt kardjovaskulari (KV), infart mijokardijaku (IM) jew puplesija] kien 582 (9.3%) fil-grupp ikkurat bi clopidogrel flimkien ma' ASA u 719 (11.4%) fil-grupp ikkurat b'ASA, li jissarraf fi tnaqqis fir-riskju relattiv (TRR) ta' 20% (95% CI ta' 10%-28%; p=0.00009) għall-grupp ikkurat bi clopidogrel flimkien ma' ASA [tnaqqis fir-riskju relattiv ta' 17% f'pazjenti li kienu kkurati b'mod konservattiv, 29% meta kellhom anġjoplastija koronarja transluminali perkutaneja (PTCA) bi stent jew mingħajru u 10% meta kellhom trapjant ta' bajpass f'arterja koronarja (CABG)].
English: This was associated with a reduction of the mean inhibition of platelet aggregation by 15% and 11%, respectively.
Maltese: Dan kien assoċjat ma' tnaqqis fl-inibizzjoni medja tal-aggregazzjoni tal-plejtlits b'15 % u b'11 % rispettivament.
English: Tablet coating: hypromellose, polydextrose, titanium dioxide (E171), quinoline yellow aluminium lake (E104), talc, maltodextrin, medium chain triglycerides and iron oxide yellow (E172).
Maltese: Il-kisi tal-pillola: hypromellose, polydextrose, titanium dioxide (E171), quinoline yellow aluminium lake (E104), talc, maltodextrin, medium chain triglycerides u iron oxide
English: Thrombotic thrombocytopenic purpura (TTP) (see section 4.4), aplastic anaemia, pancytopenia, agranulocytosis, severe thrombocytopenia, granulocytopenia, anaemia, acquired haemophilia A.
Maltese: Purpura Tromboċitopenika Trombotika (TTP) (ara sezzjoni 4.4), anemija aplastika, panċitopenija agranuloċitosi tromboċitotopenija severa, emofilja A akwiżita, granuloċitopenija, anemija.
English: • Renal impairment
Maltese: • Indeboliment renali
English: After the 300 mg/75 mg dose regimen, antiplatelet responses were decreased in the poor metabolisers with mean IPA (5 μM ADP) of 24% (24 hours) and 37% (Day 5) as compared to IPA of 39% (24 hours) and 58% (Day 5) in the extensive metabolisers and 37% (24 hours) and 60% (Day 5) in the intermediate metabolisers.
Maltese: Wara s-sistema ta' dożaġġ ta' 300 mg/75 mg, ir-risponsi kontra l-plejtlits tnaqqsu filmetabolizzaturi dgħajfa b'IPA medja (5 μM ADP) ta' 24% (24 siegħa) u 37% (Jum 5) meta mqabbel ma' IPA ta' 39% (24 siegħa) u 58% (Jum 5) fil-metabolizzaturi estensivi u 37% (24 siegħa) u 60% (Jum 5) fil-metabolizzaturi intermedji.
English: • probenecid, benzbromarone, or sulfinpyrazone, medicines used to treat gout,
Maltese: - probenicid, benzbromarone jew sulfinpyrazone, mediċini użati fil-kura tal-gotta,
English: 10 film-coated tablets 14 film-coated tablets 28 film-coated tablets 30 film-coated tablets 50 film-coated tablets 90 film-coated tablets 100 film-coated tablets
Maltese: 10 pilloli miksijin b'rita 14-il pillola miksija b'rita 28 pillola miksija b'rita 30 pillola miksija b'rita 50 pillola miksija b'rita 90 pillola miksija b'rita 100 pillola miksija b'rita
English: Each film-coated tablet contains 117.8 mg of lactose (as lactose monohydrate).
Maltese: Kull pillola miksija b'rita fiha 117.8 mg ta' lactose (bħala lactose monohydrate).
English: Hypoglycaemia*, gout* (see section
Maltese: Ipogliċemija*, gotta* (ara sezzjoni 4.4)
English: Treat other signs of intoxication symptomatically.
Maltese: reazzjonijiet ta' sensittività eċċessiva.
English: This benefit was mostly driven by the statistically significant reduction in the incidence of MI [287 (4.6%) in the clopidogrel plus ASA group and 363 (5.8%) in the ASA group].
Maltese: Dan il-benefiċċju ġie l-iktar mit-tnaqqis li kien statistikament sinifikanti tal-inċidenza ta' MI [287 (4.6%) fil-grupp ikkurat bi clopidogrel flimkien ma'ASA u 363 (5.8%) fil-grupp ikkurat b'ASA].
English: • fluconazole, voriconazole, ciprofloxacin, or chloramphenicol, medicines to treat bacterial and fungal infections,
Maltese: - fluconazole, voriconazole, ciprofloxacin, jew chloramphenicol, mediċini għall-kura ta'
English: Tablet coating: hypromellose, polydextrose, titanium dioxide (E171), talc, maltodextrin, medium chain triglycerides, iron oxide yellow (E172).
Maltese: Il-kisi tal-pillola: hypromellose, polydextrose, titanium dioxide (E171), talc, maltodextrin, medium chain triglycerides, iron oxide yellow (E172). carmine (E120), iron oxide red
English: • Adults and elderly population
Maltese: • Adulti u nies akbar fl-età
English: • Hypersensitivity to non-steroidal anti-inflammatory drugs (NSAIDs) and syndrome of asthma, rhinitis, and nasal polyps.
Maltese: • Sensittività eċċessiva għall-mediċini antiinfjammatorji li mhumiex sterojdi (NSAIDs) u sindromu ta' ażżma, rinite u qarnit fl-imnieħer.
English: • Severe hepatic impairment.
Maltese: • Indeboliment epatiku sever .
English: The number of patients experiencing the co-primary endpoint (CV death, MI, stroke or refractory ischaemia) was 1,035 (16.5%) in the clopidogrel plus ASA group and 1,187 (18.8%) in the ASA group, a 14% relative risk reduction (95% CI of 6%-21%, p=0.0005) for the clopidogrel plus ASA group.
Maltese: In-numri ta' pazjenti li kellhom punt ko-primarju ta' tmiem (mewt KV, IM, puplesija jew iskemija li mhux qed tirrispondi għall-kura) kien 1,035 (16.5%) fil-grupp ikkurat bi clopidogrel flimkien ma' ASA u 1,187 (18.8%) fil-grupp ikkurat b'ASA, tnaqqis ta' 14% fir-riskju relattiv) (95% CI ta' 6%21%, p= 0.0005) għall-grupp ikkurat bi clopidogrel flimkien ma'ASA.
English: In vitro and in vivo, clopidogrel is metabolised according to two main metabolic pathways: one mediated by esterases and leading to hydrolysis into its inactive carboxylic acid derivative (85% of circulating metabolites), and one mediated by multiple cytochromes P450.
Maltese: In vitro u in vivo, clopidogrel jiġi mmetabolizzat permezz ta' żewġ sensiliet ta' reazzjonijiet metaboliċi: waħda bl-intervent ta' esterases u li twassal għall-idroliżi fid-derivattiv inattiv tiegħu carboxylic acid (85% tal-metaboliti fiċċirkulazzjoni),u waħda bl-intervent ta' ċitokromi P450 multipli. Clopidogrel jiġi mmetabolizzat lewwel f'metabolit intermedjarju 2-oxo-clopidogrel.
English: The clinical relevance of this interaction is uncertain.
Maltese: Ir-relevanza klinika ta' din l-interazzjoni hija inċerta.
English: Musculo-skeletal bleeding (haemarthrosis), arthritis, arthralgia, myalgia
Maltese: Demm fil-muskolu u flgħadam (emartrożi), artrite, artralġija, majalġja
English: Each film-coated tablet contains 102.6 mg of lactose (as lactose monohydrate).
Maltese: Kull pillola miksija b'rita fiha 102.6 mg ta' lactose (bħala lactose monohydrate).
English: Patients were randomised to clopidogrel (300 mg loading dose followed by 75 mg/day, N=6,259) plus ASA (75-325 mg once daily) or ASA alone (N=6,303), (75-325 mg once daily) and other standard therapies.
Maltese: Il-pazjenti kienu randomised għal clopidogrel (doża tal-bidu ta' 300 mg u wara 75 mg/jum, N = 6,259) flimkien ma' ASA (75-325 mg darba kuljum) jew ASA waħdu (N = 6,303), (75-325 mg darba kuljum) u terapiji oħra normali.
English: In patients who remained on therapy within five days of bypass graft surgery, the event rate was 9.6% for clopidogrel plus ASA, and 6.3% for placebo plus ASA.
Maltese: F'pazjenti li baqgħu jieħdu l-kura fil-ħamest ijiem sal-operazzjoni tal-bypass graft, irrata tal-avveniment kienet 9.6% għal clopidogrel + ASA, u 6.3% għal ASA waħdu.
English: • stomach ulcer
Maltese: • perforazzjoni tal-ulċera
English: • sensation of tingling and numbness.
Maltese: • sensazzjoni ta' tnemnim u tirżiħ
English: • The other ingredients are: Tablet core: lactose monohydrate, microcrystalline cellulose, hydroxypropylcellulose 100 cP, crospovidone (type A), stearic acid, croscarmellose sodium, hydrogenated vegetable oil and sodium lauril sulfate.
Maltese: hydroxypropylcellulose 100 cP, crospovidone (tip A), stearic acid, croscarmellose sodium, hydrogenated vegetable oil u sodium lauril sulfate.
English: Following toxic doses (10-20 g), the plasma half-life may be increased to over 20 hours.
Maltese: Wara dożi tossiċi (10-20 g), il-half-life fil-plażma jista' jiżdied għal iktar minn 20 siegħa.
English: Inconsistent data on the clinical implications of this pharmacokinetic (PK)/pharmacodynamic (PD) interaction in terms of major cardiovascular events have been reported from both observational and clinical studies.
Maltese: Dejta inkonsistenti dwar l-implikazzjonijiet kliniċi ta' din l-interazzjoni farmakokinetika (PK)/farmakodinamika (PD) f'termini ta' avvenimenti kardjovaskulari ewlenin ġiet irrapportata sew mill-osservazzjoni kif ukoll mill-istudji kliniċi.
English: The absolute risk for cardiovascular malformation was increased from less than 1%, up to approximately 1.5%.
Maltese: Ir-riskju assolut ta' difett fil-formazzjoni kardjovaskulari żdied minn inqas minn 1 %a madwar 1.5 %.
English: Interactions with the following medicinal products have been reported with ASA:
Maltese: Ġew irrapportati interazzjonijiet bejn ASA u l-prodotti mediċinali li ġejjien:
English: Clopidogrel/Acetylsalicylic acid Teva contains clopidogrel and acetylsalicylic acid (ASA) and belongs to a group of medicines called antiplatelet medicinal products.
Maltese: Clopidogrel/Acetylsalicylic acid Teva fih clopidogrel u acetylsalicylic acid (ASA) u jifforma parti minn grupp ta' mediċini msejħa prodotti mediċinali ta' kontra l-plejtlets.
English: In CURE, 823 (6.6%) patients received concomitant GPIIb/IIIa receptor antagonist therapy.
Maltese: F'CURE ,823 pazjent irċevew fl-istess ħin terapija ta' antagonista għar-riċettur GPIIb/IIIa.
English: The CYP2C19*2 and CYP2C19*3 alleles account for the majority of reduced function alleles in Caucasian (85%) and Asian (99%) poor metabolisers.
Maltese: L-alleli CYP2C19*2 u CYP2C19*3 jgħoddu għal parti l-kbira tal-alleli b'funzjoni mnaqqsa fil-metabolizzaturi dgħajfa Kawkażi (85 %) u Asjatiċi (99%).
English: • muscular pain
Maltese: • uġigħ muskolari
English: Consistent with the above results, in a meta analysis including 6 studies of 335 clopidogrel-treated subjects at steady state, it was shown that active metabolite exposure was decreased by 28% for intermediate metabolisers, and 72% for poor metabolisers while platelet aggregation inhibition (5 μM ADP) was decreased with differences in IPA of 5.9% and 21.4%, respectively, when compared to extensive metabolisers.
Maltese: Konsistenti ma' dawn ir-riżultati, f'meta-analiżi li inkludiet 6 studji ta' 335 suġġett ikkurat b'clopidogrel f'livell fiss, ġie muri li l-espożizzjoni tal-metabolit attiv tnaqqas b'28% għallmetabolizzaturi intermedji, u 72% għall-metabolizzaturi dgħajfa filwaqt li l-inibizzjoni talaggregazzjoni tal-plejtlits (5 μM ADP) tnaqqset b'differenzi fl-IPA ta' 5.9% u 21.4% rispettivament, meta mqabbel ma' metabolizzaturi estensivi.
English: Clopidogrel/Acetylsalicylic acid Teva is supplied in blisters in pack sizes of 10, 14, 28, 30, 50, 90 and 100 film-coated tablets or in bottles in a pack size of 30 film-coated tablets.
Maltese: Clopidogrel/Acetylsalicylic acid Teva jiġi f'folji f'daqsijiet ta' pakketti ta' 10, 14, 28, 30, 50, 90 u 100 pillola miksijin b'rita jew fi fliexken b'daqs tal-pakkett ta' 30 pillola miksijin b'rita.
English: Depression of the nervous system can lead to coma, cardiovascular collapse and respiratory arrest.
Maltese: Tnaqqis fl-attività tassistema nervuża tista' twassal għal koma, kollass kardjovaskulari u insuffiċjenza respiratorja.
English: Clopidogrel/Acetylsalicylic acid Teva contains lactose.
Maltese: Clopidogrel/Acetylsalicylic acid Teva fih il-lactose.
English: The 2x2 factorial design COMMIT trial included 45,852 patients presenting within 24 hours of the onset of the symptoms of suspected MI with supporting ECG abnormalities (i.e. ST elevation, ST depression or left bundle-branch block).
Maltese: L-għamla ta' 2x2 factorial tal-prova COMMIT inkludiet 45,852 pazjent li ppreżentaw fi żmien 24 siegħa mill-ħin li bdew is-sintomi ta' suspett ta' MI b'abnormalitajiet fl-ECG suġġestivi t'hekk (jiġifieri ST elevat, ST imniżżel jew blokk tal-bundle branch tax-xellug).
English: Interactions with the following medicinal products with higher (anti-inflammatory) doses of ASA have also been reported: angiotensin converting enzyme (ACE) inhibitors, acetazolamide, anticonvulsants (phenytoin and valproic acid), beta blockers, diuretics, and oral hypoglycemic agents.
Maltese: B'dożi ogħla (anti-infjammatori) ta' ASA ġew irrapportati wkoll interazzjonijiet mal-prodotti mediċinali li ġejjien: inibituri tal-enzima li tikkonverti anġjotensin (ACE), acetazolamide, mediċini kontra l-konvulżjonijiet (phenytoin u valproic acid), beta-blokkanti, dijuretiċi u sustanzi ipogliċemiċi li jittieħdu mill-ħalq.
English: The CURE study included 12,562 patients with non-ST segment elevation acute coronary syndrome (unstable angina or non-Q-wave myocardial infarction), and presenting within 24 hours of onset of the most recent episode of chest pain or symptoms consistent with ischaemia.
Maltese: L-istudju CURE kien jinkludi 12,562 pazjent bis-sindromu koronarju akut tas-segment mhux-ST elevat (anġina instabbli jew infart mijokardijaku li mhux-mewġa-Q), u li ddaħħlu fl-istudju f'24 siegħa mill-iktar episodju reċenti ta' uġigħ fis-sider jew sintomi konsistenti mal-iskemija.
English: 74770 Opava-Komarov Czech Republic
Maltese: Opava-Komarov Ir-Repubblika Ċeka
English: • The active substances are clopidogrel and acetylsalicylic acid.
Maltese: • Is-sustanzi attivi huma clopidogrel u acetylsalicylic acid.
English: There is no evidence that other medicinal products that reduce stomach acid such as H2 blockers (except cimetidine which is a CYP2C19 inhibitor) or antacids interfere with antiplatelet activity of clopidogrel.
Maltese: M'hemm ebda evidenza li prodotti mediċinali oħra li jnaqqsu l-aċidu fl-istonku bħall-imblokkaturi ta' H2 (ħlief cimetidine li huwa inibitur ta' CYP2C19) jew l-antaċidi jaffettwaw l-attività kontra l-plejtlits ta' clopidogrel.
English: The incidence of severe cases was similar for clopidogrel and ASA.
Maltese: Linċidenza ta' każi severi kienet simili għal clopidogrel u għal ASA.
English: - renal dysfunction, which may progress to renal failure with oligo-hydroamniosis;
Maltese: - disfunzjoni renali li tista' twassal għall-insuffiċjenza renali b'oligo-idroamnjożi;
English: Respiratory tract bleeding (haemoptysis, pulmonary haemorrhage), bronchospasm, interstitial pneumonitis, non-cardiogenic pulmonary edema with chronic use and in the context of a hypersensitivity reaction due to acetylsalicylic acid*, eosinophilic pneumonia.
Maltese: Dmija fil-passaġġ respiratorju (emoptisis, emorraġija fil-pulmun), bronkospażmu, pnewmonite interstizjali, pulmonite eosinofilika, edima pulmonarja li mhijiex kardjoġenika wara l-użu kroniku u f'kuntest ta' reazzjoni ta' sensittività eċċessiva minħabba acetylsalicylic acid*.
English: Other medicinal products: A number of other clinical studies have been conducted with clopidogrel and other concomitant medicinal products to investigate the potential for pharmacodynamic and pharmacokinetic (PK) interactions.
Maltese: Prodotti mediċinali oħrajn: Saru numru ta' studji kliniċi oħra bi clopidogrel u prodotti mediċinali oħra li ngħataw flimkien biex tiġi investigata l-possibilità ta' interazzjonijiet farmakodinamiċi u farmakokinetiċi.
English: Fifteen percent (15.0%) of patients in the clopidogrel plus ASA group and 21.7% in the group treated with ASA alone reached the primary endpoint, representing an absolute reduction of 6.7% and a 36% odds reduction in favor of clopidogrel (95% CI: 24, 47%; p <0.001), mainly related to a reduction in occluded infarct-related arteries.
Maltese: 0%) tal-pazjenti fil-grupp tal-clopidogrel flimkien ma' ASA u 21.7% tal-grupp ikkurat b'ASA waħdu laħqu l-punt primarju u aħħari, li jirrappreżentaw tnaqqis assolut ta' 6.7% u 36% ta' tnaqqis probabbli favur clopidogrel (95% CI: 24, 47%; p <0.
English: Pack sizes of 14, 28 and 30 film-coated tablets.
Maltese: Daqsijiet tal-pakkett ta' 14, 28 u 30 pillola miksijin b'rita.
English: • jaundice
Maltese: • sturdament
English: • burning in stomach and/or oesophagus
Maltese: • ħruq fl-istonku u/jew fl-esofagu
English: The safety and efficacy of clopidogrel plus ASA have been evaluated in three double-blind studies involving over 61,900 patients: the CURE, CLARITY and COMMIT studies, comparing clopidogrel plus ASA to ASA alone, both treatments given in combination with other standard therapy.
Maltese: Is-sigurtà u l-effikaċja ta' clopidogrel flimkien ma' ASA kienu evalwati f'tliet studji double blind li involvew 'il fuq minn 61,900 pazjent: l-istudji CURE, CLARITY u COMMIT , li qabblu clopidogrel flimkein ma' ASA ma' ASA waħdu, iż-żewġ trattamenti ngħataw flimkien ma' terapija oħra li soltu tingħata.
English: Reye's Syndrome is a very rare disease which can be fatal.
Maltese: Is-sindromu ta' Reye hija marda rari ħafna li tista' tkun fatali.
English: The lethal dose of acetylsalicylic acid is 25-30 g. Plasma salicylate concentrations above 300 mg/l (1.67 mmol/l) suggest intoxication.
Maltese: Konċentrazzjonijiet fil-plażma 'l fuq minn 300 mg/l (1.67 mmol/l) ta' saliċilati jindikaw intossikazzjoni.
English: • the foetus to:
Maltese: • il-fetu għal:
English: ASA: The following symptoms are associated with moderate intoxication: dizziness, headache, tinnitus, confusion and gastrointestinal symptoms (nausea, vomiting and gastric pain).
Maltese: Is-sintomi li ġejjien huma assoċjati ma' intossikazzjoni moderata: sturdament, uġigħ ta' ras, żanżin fil-widnejn (tinnitus), konfużjoni, u sintomi gastro-intestinali (dardir, rimettar u uġigħ gastriku).
English: Published frequencies for the poor CYP2C19 metaboliser genotypes are approximately 2% for Caucasians, 4% for Blacks and 14% for Chinese.
Maltese: Skont kif ippubblikat, il-frekwenza ta' ġenotipi ta' metabolizzaturi dgħajfa ta' CYP2C19 huma madwar 2% għall-Kawkasi, 4% għas-Suwed u 14% għaċĊiniżi.
English: • ST segment elevation acute myocardial infarction in medically treated patients eligible for
Maltese: • Infart mijokardijaku akut bis-segment ST elevat, f'pazjenti ttrattati bil-mediċini u eliġibbli għat
English: While you are taking Clopidogrel/Acetylsalicylic acid Teva:
Maltese: Tiħux Clopidogrel/Acetylsalicylic acid Teva:
English: NAME OF THE MARKETING AUTHORISATION HOLDER Teva Pharma B.V.
Maltese: TAD-DETENTUR TAL-AWTORIZZAZZJONI GĦAT-TQEGĦID FIS-SUQ Teva Pharma B.V.
English: Clopidogrel/Acetylsalicylic acid Teva is indicated for the prevention of atherothrombotic events in adult patients already taking both clopidogrel and acetylsalicylic acid (ASA).
Maltese: Clopidogrel/Acetylsalicylic acid Teva huwa indikat għall-prevenzjoni ta' avvenimenti aterotrombotiċi f'pazjenti adulti li diġà qegħdin jieħdu kemm clopidogrel u kemm acetylsalicylic acid (ASA).
English: Film-coated tablet 14 film-coated tablets 28 film-coated tablets 30 film-coated tablets
Maltese: Pillola miksija b'rita 14-il pillola miksija b'rita 28 pillola miksija b'rita 30 pillola miksija b'rita
English: Following absorption, the ASA in the combination of clopidogrel/acetylsalicylic acid is hydrolyzed to salicylic acid with peak plasma levels of salicylic acid occurring within 1 hour of dosing, such that plasma levels of ASA are essentially undetectable 1.5-3 hours after dosing.
Maltese: Wara li jiġi assorbit, l-ASA f'Clopidogrel/Acetylsalicylic acid Teva jiġi idrolizzat għal salicylic acid bl-ogħla livelli ta' salicylic acid fil-plażma jintlaħqu fi żmien siegħa minn wara li tittieħed iddoża, waqt li ftit li xejn ma ssib livelli ta' ASA fil-plażma wara 1.5-3 sigħat mid-doża.
English: In CLARITY, there was an overall increase in bleeding in the clopidogrel plus ASA group vs. the group taking ASA alone.
Maltese: Fi CLARITY, kien hemm żieda totali fid-dmija fil-grupp ta' clopidogrel + ASA kontra l-grupp li ħadu biss ASA .
English: 5.2 Pharmacokinetic properties Clopidogrel:
Maltese: .2 Tagħrif farmakokinetiku
English: Although the administration of clopidogrel 75 mg/day did not modify the pharmacokinetics of S-warfarin or International Normalised Ratio (INR) in patients receiving long-term warfarin therapy, coadministration of clopidogrel with warfarin increases the risk of bleeding because of independent effects on hemostasis.
Maltese: Għalkemm l-għoti ta' clopidogrel 75 mg/jum ma mmodifikax il-farmakokinetika ta' S-warfarin jew ilProporzjon Normalizzat Internazzjonali (INR) f'pazjenti li rċevew terapija għal żmien twil ta' warfarin, l-għoti flimkien ta' clopidogrel ma' warfarin iżid ir-riskju ta' fsada minħabba effetti indipendenti fuq l-emostasi.
English: Serious haemorrhage, haemorrhage of operative wound, vasculitis, hypotension
Maltese: Emorraġija serja, emorraġija ta' ġerħa ta' wara operazzjoni, vaskulite, ipotensjoni
English: Clopidogrel/Acetylsalicylic acid Teva is supplied in blisters in pack sizes of 14, 28 and 30 film-coated tablets or in bottles in a pack size of 30 film-coated tablets.
Maltese: Clopidogrel/Acetylsalicylic acid Teva jiġi f'folji f'daqsijiet ta' pakketti ta' 14, 28 u 30 pillola miksijin b'rita jew fi fliexken f'daqs tal-pakkett ta' 30 pillola miksijin b'rita.
English: Non-cardiogenic pulmonary edema can occur with acute and chronic acetylsalicylic acid overdose (see section 4.8).
Maltese: Edima pulmonari li mhijiex kardjoġenika tista' sseħħ b'doża eċċessiva akuta u kronika ta' acetylsalicylic acid (ara sezzjoni 4.8).
English: As a dual antiplatelet agent, the combination of clopidogrel/acetylsalicylic acid should be used with caution in patients who may be at risk of increased bleeding from trauma, surgery or other pathological conditions and in patients receiving treatment with other NSAIDs including Cox-2 inhibitors, heparin, glycoprotein IIb/IIIa inhibitors, selective serotonin reuptake inhibitors (SSRIs), or thrombolytics.
Maltese: Bħala sustanza li għandha azzjoni dupliċi kontra lplejtlets, il-kombinazzjoni ta' clopidogrel/acetylsalicylic acid għandha tintuża b'kawtela f'pazjenti li jista' jkollhom riskju ta' iktar dmija minn trawma, operazzjoni jew kondizzjonijiet patoloġiċi oħra u pazjenti li jkunu qed jirċievu l-kura b'NSAIDs oħra li jinkludu l-inibituri ta' Cox-2, heparin jew inibituri ta' glycoprotein IIb/IIIa, jew inibituri selettivi tal-ġbir mill-ġdid ta' serotonin (SSRIs) .
English: Very rare, not known
Maltese: Rari ħafna,mhux magħruf*
English: Furthermore, the pharmacodynamic activity of clopidogrel was not significantly influenced by the co-administration of phenobarbital or oestrogen.
Maltese: Ukoll, lattività farmakodinamika ta' clopidogrel ma ġietx influwenzata b'mod sinifikanti mit-teħid flimkien ma' phenobarbital jew oestrogen.